EMA's Guido Rasi Receives Leadership Award
EMA's Executive Director, Guido Rasi received the 2014 European Rare Disease Leadership Award 2014.
The European Medicines Agency's Executive Director, Guido Rasi, together with Paola Testori Coggi from the European Commission and Luca Pani from AIFA, have received the 2014 European Rare Disease Leadership Award 2014.
The award has been given by EURORDIS, a non-governmental patient-driven alliance of patient organizations representing 614 rare disease patient groups in 58 countries.
Today, 28 February 2014, is Rare Disease Day, and EURORDIS is planning a series of activities and events, including a television interview in Kenya, a Fun Play Day in Lebanon, an informational awareness-raising campaign in Paraguay, a march in Austria, an auction in Canada, a photo exhibit in China, and a seminar in India. It says thousands of participants from over 80 countries will be involved in the event.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
